Override sizing to 50% two-tranche Buy; first leg at $371 with $361 stop, second leg conditional on Q3 confirmation
Override Research Manager and Trader sizing to 50% two-tranche architecture. First tranche: 25% at $371 with $361 hard stop (2.7% defined downside, $353.59 as emergency exit trigger). Second tranche: 25% deferred to post-Oct 13 Q3 earnings confirmation. Blended expected return is +2.1% (+0.9% first tranche including 1.2% 6-month dividend capture, +3.3% second tranche post-confirmation). This explicitly addresses the 10-07 binding reflection requirement for an explicit expected-return model and forbids negative-space reasoning of 'we haven't tried Buy yet.' The conservative analyst's valid points on asymmetric stress (1:5 vs 2:1), thin-pool sentiment indicators, and non-recurring working capital tailwind shape the conservative sizing. Price target of $432.0 implies 17–24% upside to normalized multiple on Forward 16.4x P/E with 45% expected EPS growth.
| Position | Action |
|---|---|
| Full conviction sizing (Research Manager 75% upper bound) | Override to 50% two-tranche default per cross-ticker insurance-level sizing lessons from V, JPM, LLY 10-07 reflections |
| First tranche deployment | 25% at $371 with $361 hard stop (2.7% defined downside, above 200 SMA at $353.59, below lower Bollinger Band at $366.64) |
| Second tranche deployment | 25% only after Oct 13 Q3 print confirms recovery: clean beat, FY26 guide maintained, no goodwill disclosure, MLR commentary ≤11% |
| Emergency exit on binary catalyst resolution | $353.59 trigger if 200 SMA breaksbearishly |
UNH at $370.95 is a materially mispriced defensive asset offering 45% EPS growth at 16.4x forward P/E with an 82% probability earnings catalyst in 5 days and a coiled technical setup.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 353.59 | bullish |
| 50 SMA | 388.51 | bearish |
| 10 EMA | 374.07 | bearish |
| MACD | -4.55 | bearish |
| MACD Histogram | +0.88 | bullish |
| RSI | 41.54 | bearish |
| Bollinger Upper Band | 382.94 | bearish |
| Bollinger Middle Band | 374.79 | neutral |
| Bollinger Lower Band | 366.64 | bearish |
| ATR (14) | 8.80 | neutral |
Support: 366.64 · 353.59 · 325 · 330 | Resistance: 374.07 · 374.79 · 382.94 · 388.51 · 400.71 · 408.5
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Oct 13 Q3 print confirms recovery: clean beat, FY26 guide maintained, no goodwill disclosure, MLR commentary ≤11%
Then: Deploy remaining 25% of position size
Earnings recovery is already demonstrated with two consecutive strong quarters
↩ rebuts: “Bear 'HOLD' based on Q4 2025 anomaly”
EV: +17.2% to +24.0% (6-12 month) · concedes: Q4 2025 anomaly was real but has been fully digested with two consecutive strong quarters; Below 50 SMA ($388.51) represents real technical resistance, though the 50 SMA is falling toward price; Wide 52-week range ($256-$462) reflects genuine volatility; Goodwill concentration at 35.7% of assets is high by conventional standards
UNH's setup is a binary event with broken expected value: the Q3 earnings catalyst has only +0.80% EV when properly calculated, the technical picture is unambiguously bearish across every indicator, and the "recovery" narrative relies on non-repeatable working capital tailwinds rather than structural earnings power.
EV: +0.80% · concedes: The balance sheet deleveraging and $31.5B liquidity are real positives, but the $9.3B reduction was driven by one-time working capital releases that won't continue at the same pace; The Polymarket 82% beat probability is directionally correct but the $402 liquidity makes it noise rather than a meaningful market signal; The moat is real but faces regulatory, antitrust, and cyber risk vectors that the market is correctly pricing as a 25% discount; The defensive rotation narrative is valid but UNH at 0.615 beta is the least rate-sensitive defensive, making it the wrong beneficiary
→ vs conservative: Position sizing at 50-75% of conviction is too conservative; with 2:1 asymmetric risk-reward and defined $353.59 stop, underweighting systematically leaves expected value on the table
→ vs conservative: Goodwill at $110.65 billion (35.7% of assets) is non-cash and does not affect operating cash flow, FCF, dividends, or buybacks; impairment would have been telegraphed in Q1/Q2 numbers which management did not flag
→ vs conservative: 50 SMA rollover at $388.51 and RSI at 41.54 are headwinds but MACD momentum shift from negative 3.15 to positive 0.88 signals downside exhaustion at major pivot level
→ vs neutral: 82% beat probability is not fully priced in; stock exhibits crisis-mode price action sitting just above lower Bollinger Band despite improving fundamentals and smart money leaning bullish
→ vs neutral: Q3 earnings is not purely binary; base case is clean print given Q1/Q2 operational performance, with 2027 Medicare Advantage Star Ratings release in October providing additional multi-quarter catalyst
→ vs neutral: HOLD recommendation implicitly assumes 1-2 week trading window, but multi-quarter thesis targets 432-460 based on fundamental re-rating within 6-12 month horizon
UNH experienced a violent regime change over 18 months—plunging from ~$578 in April 2025 to under $228 by August 2025 (a ~60% drawdown), then recovering to ~$431 by July 2026 before settling into the $365-$400 range. The stock is currently in a bearish short-term consolidation within a still-improving longer-term framework, trading just above the 200 SMA ($353.59) as critical support but failing at the 50 SMA ($388.51) and lower Bollinger Band ($366.64). Key resistance overhead includes the 50 SMA at $388.51, with support anchored at the 200 SMA ($353.59) and the Bollinger Lower Band ($366.64). The ATR has compressed by ~31% from its July peak of $12.72 to $8.80, suggesting a coiled volatility setup. The base case scenario (~50% probability) envisions the stock chopping between $367 and $388 until a directional breakout occurs.
Market Cap
$332.96B
Beta
0.615
Shares Outstanding
~905M
P/E (TTM)
23.86
Forward P/E
16.41
PEG Ratio
1.02
P/B
3.41
EPS (TTM)
$15.55
Forward EPS
$22.61
Dividend Yield
2.47%
52-Week High
$461.62
52-Week Low
$255.97
50-Day MA
$391.01
200-Day MA
$357.04
Revenue (TTM)
$450.53B
Gross Profit (TTM)
$88.86B
EBITDA (TTM)
$26.68B
Net Income (TTM)
$14.12B
Operating Margin
7.13%
Profit Margin
3.14%
Free Cash Flow (TTM)
$24.27B
Q2 2025 Revenue
$111.62B
Q2 2025 Net Income
$3.41B
Q2 2025 Diluted EPS
$3.74
Q2 2025 Operating CF
$7.19B
Q2 2025 FCF
$6.30B
Q3 2025 Revenue
$113.16B
Q3 2025 Net Income
$2.35B
Q3 2025 Diluted EPS
$2.59
Q3 2025 Operating CF
$5.95B
Q3 2025 FCF
$5.06B
Q4 2025 Revenue
$113.22B
Q4 2025 Net Income
$0.01B
Q4 2025 Diluted EPS
$0.01
Q4 2025 Operating CF
$1.11B
Q4 2025 FCF
$0.16B
Q1 2026 Revenue
$111.72B
Q1 2026 Net Income
$6.28B
Q1 2026 Diluted EPS
$6.90
Q1 2026 Operating CF
$8.91B
Q1 2026 FCF
$8.15B
Q2 2026 Revenue
$112.03B
Q2 2026 Net Income
$5.48B
Q2 2026 Diluted EPS
$6.04
Q2 2026 Operating CF
$11.05B
Q2 2026 FCF
$10.25B
YTD 2026 EPS
$12.94
Total Assets
$309.73B
Total Liabilities
$203.78B
Total Stockholders' Equity
$98.45B
Net Debt
$44.74B
Total Debt
$73.33B
Long-term Debt
$69.50B
Cash & Equivalents
$28.59B
Short-term Investments
$2.88B
Investments & Advances
$57.72B
Goodwill
$110.65B
Other Intangibles
$19.75B
Net PPE
$10.76B
Working Capital
-$24.96B
Tangible Book Value
-$31.95B
Debt/Equity
69.21
Total Equity Growth
$4.33B
Return on Equity (ROE)
14.15%
Return on Assets (ROA)
4.87%
CapEx (Purchases of PPE)
-$0.80B
Cash Dividends Paid
-$2.09B
Stock Repurchases
-$1.65B
Long-term Debt Repayment
-$1.00B
Net Change in Cash
+$631M
FCF Payout Ratio
3.6%
Annualized FCF
$24.27B
Strengths
Concerns
HOLD with a bullish bias — UNH presents a compelling medium-term value setup with attractive forward valuation (P/E 16.41x, +45% EPS growth), robust FCF generation ($24.27B TTM), active deleveraging ($9.3B net debt reduction in 6 months), and recovering earnings momentum (Q1-Q2 2026 EPS >100% YoY); the technical setup (above 200-day MA, below 50-day MA) suggests an appropriate accumulation zone for 6-12 month horizons, though position sizing discipline is warranted given the stock's 80% annual range.
Macro: No 2026 Fed rate cuts (96% odds); recession odds benign (US 6%, UK 7%, Japan 4%); oil ~$103 (down post-Iran-deescalation, disinflationary); gold $4,131.80 (+0.44%, risk-off bid intact); rapid bond yield moves flagged as warning sign; mortgage rates at ~3-year highs. FRED macro series unavailable (API key missing); analysis grounded in prediction markets and qualitative news signals.